Reverse cholesterol transport;Reverzní transport cholesterolu

Cor et Vasa

Volumn 48, Issue 3, 2006, Pages 114-120

  Lesná, Ivana Králová ^a   Kovář, Jan ^a   Poledne, Rudolf ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Atherogenesis; HDL; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G1; ABC TRANSPORTER G4; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CELL TRANSPORT; CHOLESTEROL ESTERIFICATION; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; DIFFUSION; DRUG MECHANISM; HOMEOSTASIS; HUMAN; LIPID ANALYSIS; MACROPHAGE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN TRANSPORT;

EID: 33645562596     PISSN: 00108650     EISSN: None     Source Type: Journal    
DOI: 10.33678/cor.2006.037     Document Type: Article

References (54)

1. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-6.
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
3. Forte TM, McCall MR, Amacher S, Nordhausen RW, Vigne JL, Mallory JB. Physical and chemical characteristics of apolipoprotein A-I-lipid complexes produced by Chinese hamster ovary cells transfected with the human apolipoprotein A-I gene. Biochim Biophys Acta 1990;1047:11-8.
4. von Eckardstein A, Hersberger M, Rohrer L. Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care 2005;8:147-52.
5. Van Eck M, Heijgers N, Yates J, et al. Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:3117-26.
6. Kiss RS, McManus DC, Franklin V, et al. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways. J Biol Chem 2003;278:10119-27.
7. Timmins JM, Lee JY, Mulya A, et al. Tissue-specific hepatic deletion of ABCA1 indicates that the liver is the primary site of HDL formation in vivo. Arterioscler Tromb Vasc Biol 2004;24:E2.
8. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74.
9. Tall AR, Lalanne F. Phospholipid transfer protein and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23: 1484-5.
10. Rosenblat M, Vaya J, Shih D, Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atheroscler 2005;179:69-77.
11. HO YK, Brown MS, Goldstein JL. Hydrolysis and excretion of cytoplasmic cholesteryl esters by macrophages: stimulation by high density lipoprotein and other agents. J Lipid Res 1980;21:391-8.
12. Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 2005; 16:19-25.
13. Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem 2001;276:23742-7.
14. Van Eck M, Pennings M, Hoekstra M, Out R, Van Berkel TJC. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005;16:307-15.
15. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J Clin Invest 2001;108:1315-20.
16. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96:1221-32.
17. Wang N, Lan D, Chen W, Matsuura F, Tall A. ATP-binding casette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004;29:101.
18. Koch S, Donarksi N, Goetze K, et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001;42:1143-51.
19. Oram JF, Brinton EA, Bierman EL. Regulation of high density lipoprotein receptor activity in cultured human skin fibroblasts and human arterial smooth muscle cells. J Clin Invest 1983;72:1611-21.
20. Ji Y, Jian B, Wang N. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997;272:20982-5.
21. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:712-9.
22. Chen W, Silver DL, Smith JD, Tall AR. Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages. J Biol Chem 2000;275:30794-800.
23. Barter PJ. Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler 2002; Suppl 3:39-47.
24. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Tromb Vasc Biol 2003;23:1732-8.
25. Nakagawa-Toyama Y, Hirano K, Tsujii K, et al. Human scavenger receptor class B type I is expressed with cell-specific fashion in both initial and terminal site of reverse cholesterol transport. Atheroscler 2005;183: 75-83.
26. Van Eck M, Van Dijk KW, Herijgers N, et al. Essential role for the (hepatic) LDL receptor in macrophage apolipoprotein E-induced reduction in serum cholesterol levels and atherosclerosis. Atheroscler 2001;154:103-12.
27. Von Eckardstein A, Langer C, Engel T, et al. ATP binding cassette transporter ABCA1 modulates the secretion of apolipoprotein E from human monocyte-derived macrophages. FASEB J 2001;15:1555-61.
28. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977; 1(8019):965-8.
29. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-6.
30. Genest J, Mc Namara J, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-9.
31. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol 2001;88 (12A):9N-13N.
32. Langmann T, Klucken J, Reil M, et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 1999;257:29-33.
33. Mazzone T. Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol 1996;7:303-7.
34. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemia. Circulation 2002;105:1399-402.
35. Biensondial RJ, Hoving GK, Levels JH, et al. Restoration of endothelial function by increasing high density lipoprotein in subjects with isolated low high density lipoprotein. Circulation 2003;107:2944-8.
36. Rosenfeld SI, Packman CH, Leddy JP. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins. J Clin Invest 1983;71:795-808.
37. Nofer J, Kehrel B, Fobker M, et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16.
38. Dufaux B, Order U, Muller R, Hollmann W. Delayed effects of prolonged exercise on serum lipoproteins. Metabolism 1986;35:105-9.
39. Karason K, Wikstrand J, Sjostrom L, Wendelhag I. Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects. Int J Obes Relat Metab Dis 1999;23:948-56.
40. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003;37:283-90.
41. Linsel-Nitschke P. Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005;4:193-205.
42. Neele DM, Kaptein A, Huisman H, de Witt EC, Princen HM. No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased. Biochem Biophys Res Commun 1998;244:374-8.
43. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001;21: 1783-9.
44. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004; 164:697-705.
45. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234-8.
46. Yamashita S, Maruyama T, Hirano K, et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis 2000;152:271-85.
47. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
48. Franceschini G, Sirtori CR, Capurso A 2nd, Weisgraber KH, Mahley RW. A-I Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66: 892-900.
49. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300.
50. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355-63.
51. Fröhlich J, Dobiášová M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003;49:1873-80.
52. Dullard RPF, von Tol A. Twenty four hour insulin infusion impairs the ability of plasma from healthy subjects and Type 2 diabetic patients to promote cellular cholesterol efflux. Atherosclerosis 2001;157:49-56.
53. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M.A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA 1997;94: 12610-5.
54. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem 2003;27;278:23699-705.